Jun 2, 2026 07:05PM
Jun 2, 2026 07:05PM
May 28, 2026 07:05AM
May 19, 2026 07:05AM
May 19, 2026 07:05AM
May 13, 2026 06:50AM
May 13, 2026 06:50AM Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
May 13, 2026 06:00AM
Mar 27, 2026 12:13AM
Mar 27, 2026 12:12AM
Mar 26, 2026 04:01PM
Mar 26, 2026 04:01PM
Mar 16, 2026 07:00AM
Feb 9, 2026 07:05AM Zenas BioPharma drug meets primary endpoint in multiple sclerosis trial
Feb 9, 2026 07:05AM
Jan 5, 2026 07:05AM
Jan 5, 2026 07:05AM
Dec 16, 2025 06:58AM
Dec 15, 2025 07:05AM
Dec 15, 2025 07:05AM
Nov 12, 2025 07:05AM Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Oct 27, 2025 07:05AM
Oct 27, 2025 07:05AM
Oct 8, 2025 05:00AM
Oct 8, 2025 05:00AM
Sep 2, 2025 07:15AM
Sep 2, 2025 07:15AM
Sep 2, 2025 07:05AM Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

323,589 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All